Invasive mould infections (IMIs), such as invasive aspergillosis or mucormycosis, are a major cause of death in patients with haematological cancer and in patients receiving long-term immunosuppressive therapy. Early diagnosis and prompt initiation of antifungal therapy are crucial steps in the management of patients with IMI. The diagnosis of IMI remains a major challenge, with an increased spectrum of fungal pathogens and a diversity of clinical and radiological presentations within the expanding spectrum of immunocompromised hosts. Diagnosis is difficult to establish and is expressed on a scale of probability (proven, probable and possible). Imaging (CT scan), microbiological tools (direct examination, culture, PCR, fungal biomarkers) and histopathology are the pillars of the diagnostic workup of IMI. None of the currently available diagnostic tests provides sufficient sensitivity and specificity alone, so the optimal approach relies on a combination of multiple diagnostic strategies, including imaging, fungal biomarkers (galactomannan and 1,3-b-D-glucan) and molecular tools. In recent years, the development of PCR for filamentous fungi (primarily Aspergillus or Mucorales) and the progress made in the standardization of fungal PCR technology, may lead to future advances in the field. The appropriate diagnostic approach for IMI should be individualized to each centre, taking into account the local epidemiology of IMI and the availability of diagnostic tests.
Introduction
Advances in cancer therapy, transplantation medicine and immunosuppressive therapy have led to a considerable increase in the number and diversity of immunocompromised hosts. While the overall prognosis of these patients has been markedly improved, opportunistic infectious diseases, such as invasive mould infections (IMIs), remain an important cause of death in a rapidly expanding population of immunocompromised hosts. Originally primarily restricted to patients with neutropenic cancer and HSCT patients, IMIs are now increasingly observed in patients with diverse types of underlying conditions, such as solid organ transplantation, solid tumours, autoimmune diseases or congenital immune disorders and in patients receiving new immunosuppressive therapies including anti-calcineurin inhibitors, TNF inhibitors or immunomodulators (anti-cytokines, kinase inhibitors, monoclonal antibodies). 1, 2 The clinical presentation of IMI in these patients may be atypical or insidious, which makes the diagnostic approach even more challenging. Moreover, the spectrum of opportunistic fungal pathogens is rapidly growing. Aspergillus fumigatus and other Aspergillus spp. [causing invasive aspergillosis (IA)] are the predominant pathogenic moulds. 3, 4 Mucor spp., Rhizopus spp. and Lichtheimia spp. (the agents of mucormycosis) are responsible for 5%-15% of IMI cases, while Fusarium spp. and Scedosporium apiospermum account for a variable proportion of IMI, depending on the geographical area. 3, 4 However, the list of moulds that are recognized as opportunistic pathogens is increasing. 5 Cryptic Aspergillus spp. (A. lentulus, A. udagawae, A. calidoustus), Lomentospora (Scedosporium) prolificans, Paecilomyces variotii, Purpureocillium lilacinum (formerly Paecilomyces lilacinus) or Scopulariopsis (Microascus) spp. are emerging fungal pathogens that may exhibit multiple antifungal resistances or may be associated with atypical extrapulmonary manifestations. [6] [7] [8] [9] [10] Based on the definitions of the European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group (MSG), the likelihood of invasive fungal infections is assessed on a scale of probability (possible, probable, proven) according to a constellation of host factors and clinical and microbiological criteria. 11 A current revision of these definitions is underway. Critical issues to be addressed in this revision are the distinction of different patterns of disease and diagnostic criteria according to the type of patient population (e.g. neutropenic patients, ICU patients, paediatric population) and the place of molecular diagnostic tools (PCR) in the diagnostic work-up of these patients.
The main aim of this review is to provide readers with an update on diagnostic approaches to IMIs focusing primarily on imaging and microbiological tests, including conventional identification and culture methods, use of fungal biomarkers [galactomannan (GM), 1,3-b-D-glucan (BDG)] and detection of nucleic acids by PCR with a special emphasis on different diagnostic algorithms in specific patient populations.
Imaging technologies
Radiology is a critical step in the diagnostic work-up of patients with suspected IMI. The role of imaging, in particular CT scan, for the early detection of pulmonary IA in immunocompromised patients has been recognized since the 1980s. 12, 13 Although clinical signs of IMI are often absent or non-specific at early stages of the disease, suggestive radiological findings are frequently the first trigger to initiate antifungal therapy. Non-enhanced high-resolution CT scanning (i.e. with a slice thickness of 1 mm) currently represents the imaging procedure of choice for the diagnosis of IMI. While chest X-ray is often performed as a first screening for suspected lung disease, its sensitivity and specificity for the diagnosis of IMI is very low. Other imaging techniques, such as MRI and positron emission tomography (PET) scanning may also have a place in the diagnosis of IMI.
CT scanning
High-resolution CT scanning is considered the optimal imaging procedure for the diagnostic work-up of IMI because of its ability to detect small nodules, as well as typical lesions of IMI such as the halo, reverse halo or air crescent signs. It should be noted that none of these lesions are pathognomonic of IMI, although they may be highly suggestive in patients with profound immunosuppression, particularly those with neutropenia. Nodules are defined as well-circumscribed round opacities of any size (usually ,30 mm). Although not specific, nodules are observed in more than two-thirds of IMIs in patients with haematological malignancies, and are uncommon in the setting of bacterial or viral infections. [14] [15] [16] [17] [18] Nodules are also frequently observed in solid organ transplant recipients. [19] [20] [21] Among lung transplant recipients, however, these findings are less specific and may be observed in association with other infectious or non-infectious lung diseases, such as post-transplant lymphoproliferative disease or lung carcinoma. 22, 23 The 'halo sign' is a pulmonary nodule surrounded by an area of ground-glass opacity, which corresponds to a lung infarct surrounded by alveolar haemorrhage. Although this sign strongly suggests a diagnosis of IMI in immunocompromised patients, it may also be observed in other lung diseases, such as bacterial or viral infections, systemic diseases (Wegener granulomatosis, sarcoidosis) or cancer. 24 The prevalence of the halo sign in IMI is variable (60%-95% in the literature) and highly dependent on the stage of the disease. It is usually present at an early stage, typically within the first 2 weeks from the onset of symptoms/signs of IMI. 14, 15, 17, 18, 25 The halo sign is also less frequently observed in non-neutropenic patients, possibly because the diagnosis of IMI is more difficult to establish and delayed in this setting. [19] [20] [21] The 'reverse halo sign' (i.e. a nodule with central ground-glass attenuation and a peripheral ring of consolidation) is strongly suggestive of pulmonary mucormycosis and is rarely observed in IA. 26, 27 However, it can also be seen in other types of lung infections or non-infectious diseases, such as cryptogenic organizing pneumonia. 24 The 'air crescent sign' (i.e. peripheral area of cavitation within a pulmonary nodule) is a non-specific sign with limited diagnostic value for IMI since it appears in later stages (usually .2 weeks after the onset of disease) and usually precedes the development of a complete cavity. 14, 15 A 'hypodense sign' (i.e. a central area of attenuation within a macronodule or mass) has also been described in the setting of IMI and may correspond to an intermediate stage between the initial halo sign and the development of cavitation with the air crescent sign. 28 Besides these 'typical' CT signs of IMI, many other non-specific lung abnormalities, such as diffuse areas of ground-glass opacity, consolidation or pleural effusion, may also be observed in this setting. 17 While the presence of well-circumscribed nodules with or without the halo sign in an immunocompromised host is more suggestive of IMI than of a bacterial or a viral infection, these later manifestations are not distinctive and have not been included in the EORTC-MSG radiological criteria of invasive fungal infections. 11 Nevertheless, any kind of lung lesion should raise the possibility of IMI if susceptible host factors are present. Particular attention should be devoted to solid organ transplant recipients (particularly lung transplant recipients) and other non-neutropenic patients, in whom the classical nodular presentation of IMI is often absent and other manifestations, such as consolidation or ground-glass opacity, may be the predominant feature. [19] [20] [21] [22] Moreover, a picture of bronchial wall thickening with centrolobular nodules, designated as tree-in-bud, is a hallmark of bronchopulmonary aspergillosis and is frequently observed in lung transplant recipients. 20, 22 High-resolution CT pulmonary angiography CT pulmonary angiography (CTPA) is used for the diagnosis of pulmonary embolism. It has been recently hypothesized that it may be useful in detecting angio-invasion and vessel occlusion in the context of IMI. 29 The utility of CTPA for the diagnosis of IMI was assessed prospectively in two studies of high-risk patients with haematological malignancies. It was found to be associated with high sensitivity and negative predictive value (NPV) for identifying proven/probable IMI. 30, 31 Positive CTPA findings were also observed in approximately one-third to one-half of patients with a diagnosis of possible IMI according to EORTC-MSG criteria. The role of CTPA in non-haematological patients with a lower degree of angio-invasion remains unknown.
MRI
The role of MRI in the diagnosis of pulmonary diseases is limited by the low proton density of lung tissue and by artefacts due to the air-tissue interface. T2-weighted turbo spin-echo imaging and the generalized autocalibrating partially parallel acquisition technique may shorten the echo time and improve image quality. This approach demonstrated a good agreement with CT findings for the detection and characterization of lung lesions in immunocompromised patients. [32] [33] [34] Compared with CT, MRI has the advantage of a radiation-free procedure and use of safer contrast agents, but is technically more fastidious and may delay the diagnostic workup without adding any additional information. Furthermore, characterization of lung lesions (in particular, nodular lesions) by MRI is not well defined and is less specific than CT. Only the target sign (enhancement of the rim surrounding an isointense area on T1-weighted images with the opposite reverse target sign on T2-weighted images) displays some specificity for IMI, but is apparent only at later stages (.10 days from onset of disease). 35 Because thoracic CT imaging does not require contrast agents, there are no contraindications for the procedure, and the role of MRI for the diagnosis of IMI or other opportunistic lung infections seems very limited. However, MRI is a diagnostic procedure of choice for the characterization of lesions of the CNS in cerebral aspergillosis. 11 Lamoth and Calandra i20 PET PET detects gamma rays from positron-emitting radionuclides, such as [ 18 F]-2-deoxyglucose (FDG), which accumulate in tumour cells and in activated granulocytes and macrophages. Cases of IMI with positive FDG-PET imaging that were falsely attributed to lung cancer have been described. 36 A few studies have assessed the specific role of FDG-PET for the diagnosis of invasive fungal infections and reported an excellent sensitivity in detecting nodular lesions previously identified by CT. 37, 38 Thus, FDG-PET may be considered in selected cases of suspected IMI for its high NPV. It may also have a role in distinguishing between invasive and noninvasive IMI, assessment of the extent of the disease, or in followup. 38, 39 However, further analyses are required to delineate its role in this context.
Microbiological diagnosis
Microbiological or histopathological documentation of IMI is crucial for therapeutic decisions and often requires invasive procedures (e.g. bronchoscopy, tissue biopsy). Despite a wide panel of tests for direct or indirect recovery of moulds in clinical specimens (cultures, PCR, antigen detection), uncertainty about the diagnosis persists in many of the cases, which are categorized as possible IMIs. Because of the limited sensitivity of all these diagnostic procedures, and concerns about specificity of some of them, a combination of various testing strategies is the hallmark of IMI diagnosis.
Histopathology and cytology
Direct examination for the presence of mycelial elements using appropriate staining (e.g. Grocott-Gomori methenamine silver, periodic acid-Schiff, potassium hydroxide-calcofluor white) should be performed on all clinical specimens, including respiratory secretions or any tissue sample. Biopsy of lesions consistent with IMI, such as lung macronodules or skin nodules, should be performed whenever possible, since visualization of mycelia constitutes a criterion for proven IMI. 11 Presumptive diagnosis (i.e. Aspergillus spp. versus Mucorales) may be attempted based on the morphological characteristics of hyphal elements. The diagnostic accuracy of histopathological and cytopathological examination for the identification of Aspergillus spp. versus other filamentous fungi has been estimated to be 78%. 40 
Culture
Cultures of lower respiratory secretions collected by bronchoscopy and bronchoalveolar lavage fluid (BAL) are part of the diagnostic work-up of invasive pulmonary mould infections. However, the yield of BAL culture is notoriously low, with a sensitivity of only 20%-50% according to the most recent multi-centre trials. 41, 42 Most cases of proven/probable IMI are diagnosed on the basis of positive radiological findings and GM only. Moreover, positive BAL culture may reflect colonization and not infection, particularly in lung transplant recipients or patients with chronic lung diseases. One study suggests that positive BAL culture for Aspergillus spp. may be associated with IA in as many as 50% of ICU patients even in the absence of high-risk host conditions. 43 Culture of BAL samples may provide crucial information for targeted antifungal therapy and is recommended in all cases of suspected IMI.
Recovery of moulds in blood cultures is extremely rare, since most of them do not usually sporulate in blood with the exception of Fusarium spp., which are recovered in 40% of cases of disseminated fusariosis. 44 Other samples from normally sterile sites, such as sinus secretions, CSF or skin biopsy, should be collected whenever IMI is suspected.
Morphological identification based on microscopic and macroscopic examination is still the method of choice for identifying filamentous fungi. Molecular sequencing targeting the ribosomal DNA (internal transcribed spacer region, 18S or 26S/28S rDNA) is increasingly used to confirm species identification in doubtful cases. However, it should be noted that these approaches allow identification of Aspergillus spp. only at the section level. Partial sequencing of specific genes (b-tubulin, calmodulin) is required for accurate identification at the species level but is not routinely performed. 45 MALDI-TOF provides promising results for the accurate identification of moulds at the species level, but standardized procedures and reference databases are required. 46 
Galactomannan (GM)
GM, a polysaccharide of the cell wall of Aspergillus spp., can be detected by the Platelia Aspergillus enzyme immunoassay (Bio-Rad Laboratories, Marne-La-Coquette, France), a double-sandwich ELISA using the rat monoclonal antibody EBA-2 directed against GM. Results are expressed as a ratio of OD compared with a control sample, with a cut-off for positivity of 0.5. The test is validated for use in serum and BAL samples and has demonstrated some utility for the diagnosis of cerebral aspergillosis on CSF samples. Higher cut-offs (0.7-1) may be considered for BAL and CSF samples. The GM test is indicated only for diagnosis of IA, but has also demonstrated good sensitivity for the diagnosis of fusariosis 47 and may be positive in cases of histoplasmosis. 48 GM testing is not useful for the diagnosis of mucormycosis. Cross-reactions may also occur with non-pathogenic fungi that are closely related to Aspergillus spp., such as the Penicillium spp. False positive reactions may be due to the presence of GM in blood-derived products, gluconatesodium-containing hydration solutions, antibiotics or food products. [49] [50] [51] Concomitant administration of piperacillin/tazobactam, which has been implicated as a cause of false positive results, 52 no longer seems to be a concern since the introduction of new formulations of the drug. 53 Two recent meta-analyses of 30 studies reported an overall sensitivity of 60%-80% and a specificity of 80%-95% for serum GM in the diagnosis of IA. 54, 55 Subanalyses in distinct populations showed that sensitivity of the test was markedly decreased in solid organ transplant recipients (40%) compared with oncohaematological neutropenic patients (60%-80%). The requirement for two consecutive tests 0.5 in serum was shown to provide the best diagnostic accuracy. 56 It is usually acknowledged that GM positivity in serum may precede the first clinical or radiological signs of IMI, as suggested by one study showing that GM (monitored twice weekly) was positive several days before CT in 80% of IMI cases. 57 However, in another study, GM monitoring twice weekly was not superior to CT scanning performed once a week, with positive GM preceding major CT signs in only 10% of cases. 58 Two meta-analyses have also assessed the performance of GM testing in BAL, demonstrating a sensitivity of 85%-90% and a specificity of 90%-95%. 59, 60 While the optimal cut-off for GM in False-positive reactions have mainly been associated with renal replacement therapy, while concomitant antibacterial therapy or bacteraemia may also be associated with elevated BDG levels. [64] [65] [66] According to the results of four large meta-analyses, the overall performance of the various b-glucan assays in serum are comparable to that of the Platelia GM assay with a sensitivity of 60%-80% and a specificity of 80%-90% for the diagnosis of invasive fungal infections. [67] [68] [69] [70] Data restricted to cohorts of oncohaematological patients suggest a high specificity (99%) with the requirement of two consecutive tests, but a limited sensitivity (62% for a single test and 50% for two consecutive tests). 68 Data on other populations, such as solid organ transplant recipients or other non-neutropenic patients, are limited and raise concerns about the specificity and PPV in this setting. 65, 71, 72 The role of BDG testing in BAL has been investigated in a few studies and seems to be limited by a poor specificity. 73 
PCR
Multiple in-house PCR assays targeting various genetic sequences (18S rDNA, 28S rDNA, 5.8S rDNA, internal transcribed spacer region, mitochondrial DNA) have been developed for the detection of Aspergillus spp. in whole blood, serum, plasma or BAL. A first metaanalysis, published in 2009, reported sensitivity and specificity of a single positive PCR in blood or serum of 88% and 75%, respectively, for the diagnosis of IA. 74 Requirement for two consecutive positive tests increased specificity to 87% and the authors concluded that a single negative test was sufficient to exclude IA, while two positive tests provided a good PPV. However, important variations in results were observed across studies, which may be at least partly due to differences in PCR methods (standard, nested or real-time PCR), procedures of DNA extraction, the choice of target sequences and primers, spectrum of detection (A. fumigatus only or all Aspergillus spp.), thresholds of detection and cut-offs to define a positive result. Lack of standardized methods prevented the inclusion of PCR within the EORTC-MSG microbiological criteria for IMI. 11 To achieve the goal of uniformity, the European Aspergillus PCR Initiative (EAPCRI) Working Group of the International Society of Human and Animal Mycoses was formed in 2006. 75 PCR protocols and performance were compared between 23 centres and recommendations were published. 76 A more recent meta-analysis demonstrated higher diagnostic accuracy for studies that were compliant with the EAPCRI recommendations. 77 Additional analyses comparing PCR testing from whole blood, plasma and serum have been performed. [78] [79] [80] [81] Use of plasma samples resulted in the best sensitivity (91%) and earlier detection, and was recommended as a first screening step. Additional testing of a serum or whole blood sample may increase the NPV from 95% to near 100%. 80 Whole blood testing provides the best specificity (96%) and may be performed as an additional test in the event of positive PCR in serum to achieve near 100% PPV. 80 It should be emphasized that most cases included in these studies were derived from oncohaematological populations. The performance of PCR testing in serum from patients with other types of immunosuppression and a potentially lesser degree of angio-invasion is unknown.
Aspergillus PCR has also demonstrated a good diagnostic accuracy in BAL, with sensitivity of 91% and specificity of 92% according to one meta-analysis. 82 However, lower sensitivity has been reported in other studies. 82, 83 High performance was also reported for PCR testing in CSF from patients with cerebral aspergillosis in two studies. 84, 85 Studies comparing the performance of PCR and fungal biomarkers in serum (GM or BDG) or BAL (GM) have yielded encouraging results, suggesting optimal diagnostic accuracy when combined. 83, [86] [87] [88] These results further support the implementation of Aspergillus PCR testing in the revised definitions of IMI by the EORTC-MSG, now that concerns about standardization of procedures have been addressed. Furthermore, various commercial multiplex real-time PCRs are now available, such as AsperGenius (PathoNostics, Maastricht, the Netherlands), SeptiFast (Roche Diagnostics GmbH, Mannheim, Germany), MycAssay Aspergillus (Myconostica Ltd, Cambridge, UK), RenDx Fungiplex (Renishaw Diagnostics Ltd, Glasgow, UK), MycoGENIE (Ademtech, Pessac, France) and PLEX-ID Broad Fungal Assay (Abbott, Abbott Park, IL, USA), some of them (e.g. AsperGenius) being also able to detect azole resistance in A. fumigatus.
88-91
Multiplex PCR assays targeting the most clinically relevant Mucorales in serum or BAL have also been developed and show promising results for the early diagnosis of mucormycosis.
92-94

Aspergillus lateral flow devices
An immunochromatographic assay for rapid point-of-care diagnosis of IA using serum or BAL has been developed [Aspergillus lateral flow device (LFD); OLM Diagnostics, Newcastle upon Tyne, UK]. 95, 96 The antigen is an Aspergillus-specific extracellular mannoprotein that is detected by JF5 monoclonal antibodies. According to a recent meta-analysis, the performance of the Aspergillus LFD is comparable to that of GM detection, with an overall sensitivity and specificity of 68% and 87% in serum and of 86% and 93% in BAL. 97 The combination of LFD with GM or PCR results in high diagnostic Lamoth and Calandra i22 accuracy with a sensitivity and specificity .90% for both serum and BAL. 73, 98, 99 The performance of LFD testing in BAL has also been assessed in non-haematological populations (ICU and solid organ transplant recipients) with similar sensitivity (80%-90%), but lower specificity (80%-85%). 100, 101 Despite promising results, few centres currently use the Aspergillus LFD, which has not yet been approved by the FDA or the EORTC-MSG committee.
Diagnostic approaches for invasive mould infections
Haematological cancer patients
For decades, empirical antifungal therapy has been the mainstay of management for persistent febrile neutropenia in patients with haematological malignancies. 102 The improvement of imaging technologies (high-resolution CT scanning) and the development of new microbiological tools (fungal biomarkers, PCR) have improved the diagnostic approach for IMI. However, few studies have prospectively investigated the usefulness of different diagnostic algorithms to identify a more targeted therapeutic strategy. Maertens et al. assessed the feasibility of a pre-emptive approach using serum GM screening and targeted antifungal therapy based on GM monitoring and a combination of clinical and radiological findings, which resulted in an estimated 78% reduction in antifungal drug use, but failed to detect one case of mucormycosis. 103 Comparable results were obtained in another feasibility study suggesting a 43% reduction of antifungal therapy, although one case of mucormycosis remained undetected. 104 Two prospective randomized trials compared an empirical antifungal therapy with a pre-emptive approach driven by GM and/or PCR monitoring. 105, 106 In the pre-emptive arm of the study, the reduction in costs of antifungal therapy was not associated with a significant increase in mortality. However, one study reported an increased incidence of IMI when compared with the empirical group. 105 In one randomized controlled trial, combining GM testing and Aspergillus PCR was shown to be superior to GM monitoring alone, with a lower incidence of IMI, decreased use of antifungal agents and higher rate of IA-free survival. 107 While this approach seems to be the most sensitive and specific to identify IA cases promptly, concern remains about the recognition of mucormycosis or other IMIs. Since neither GM nor BDG are able to detect fungal species of the order Mucorales, the second most frequent cause of IMI, there is a need to develop other non-culture-based diagnostic tests, such as the multiplex PCRs described previously. [92] [93] [94] In addition to the empirical and pre-emptive strategies, a third approach consists of universal posaconazole prophylaxis to prevent both IA and mucormycosis. Posaconazole is superior to fluconazole or itraconazole when used as prophylaxis in haematological cancer patients with chemotherapy-induced neutropenia or graft-versus-host disease following allogeneic HSCT. 108, 109 Posaconazole-treated patients had a lower incidence of IMIs and better survival. The numbers needed to treat to prevent one invasive fungal infection and one death were estimated to be 27 and 35, respectively. 110 Two other randomized studies failed to demonstrate the superiority of voriconazole over fluconazole or itraconazole as antifungal prophylaxis for allogeneic HSCT in terms of IMI incidence and overall survival. 111, 112 A possible negative impact of widespread use of antifungal prophylaxis may be a shift in the epidemiology of IMIs, with an increasing rate of nonAspergillus moulds being suggested by some studies. [113] [114] [115] A recent study addressed the additional role of serial GM testing in serum in patients receiving posaconazole prophylaxis, concluding that GM screening was unreliable in this setting with a high rate of false positive results (PPV 12%). 116 In contrast, PPV was 89% for diagnostic-driven GM testing based on the clinical suspicion of IMI in this setting. Similarly, Aspergillus PCR screening was associated with modest PPV in patients receiving antifungal prophylaxis (only 5% versus 62% in patients not receiving prophylaxis). 117 Figure 1(a) and (b) propose algorithms for a pre-emptive strategy and a prophylactic approach, respectively, for the prevention of IMI in high-risk haematological cancer patients. The appropriate strategy (i.e. prophylactic versus empirical versus pre-emptive) should be defined at each individual haematology centre taking into account the incidence of IMI, the epidemiology of IMI (IA and mucormycosis), the availability of diagnostic tests (GM, BDG, PCRs) and the cost of antifungal therapy.
Solid organ transplant recipients
Diagnostic approaches for IMI in solid organ transplant recipients or other immunosuppressed patients are not well defined. One possible algorithm is shown in Figure 1(c) . Because the incidence of IMI in these populations is lower than in patients with haematological cancer, there is no evidence that serial testing of fungal biomarkers is useful. Moreover, the limited sensitivity and specificity of both GM and BDG in serum in this setting raises some doubt about their role in correctly identifying patients in whom antifungal therapy is justified. For instance, for a population with an incidence of IMI of 2%-3%, the PPV of GM or BDG would not exceed 20%. Abnormal findings on thoracic CT scan usually represent the first sign of IMI and the trigger for further investigations. Because CT imaging of IMI in these populations is less specific and may be more diverse, any new lung infiltrate or circumscribed lesion should prompt bronchoscopy and BAL analyses, which look for fungi in addition to other offending microorganisms (bacteria, viruses). Antifungal therapy should be considered for immunosuppressed patients with new abnormal CT findings and positive GM or PCR, or culture for a pathogenic fungus in the absence of another documented aetiology.
Conclusions
The diagnosis of IMI remains a major challenge, with an increased spectrum of pathogens and a diversity of clinical and radiological presentations within the expanding spectrum of immunocompromised hosts. On the one hand, the threshold for starting antifungal therapy should be low because of the high mortality of these opportunistic infections. On the other hand, the lack of specificity of the clinical signs of IMI often leads to excessive use of antifungal agents with associated adverse events, problems from drug interactions and increased costs. None of the currently available diagnostic tests provides sufficient sensitivity and specificity alone, so the optimal approach relies on a combination of multiple diagnostic strategies, including imaging, fungal biomarkers (GM and BDG) and molecular tools. In recent years, the development of PCR for filamentous fungi (primarily Aspergillus or Mucorales) and the progress made in the standardization of fungal PCR technology have been important advances in the field, but these molecular diagnostic tools are not Lamoth and Calandra i24 available in many centres. Whether these improvements in diagnostic strategies for IMI have an impact on outcome is still difficult to assess. However, recent trials or cohort studies using a GM-based diagnostic approach have reported lower mortality rates compared with historical controls. 41, 42, 118 Funding This Supplement was funded by Basilea Pharmaceutica International Ltd, Basel, Switzerland. Editorial support was provided by a freelance medical writer (C. Dunstall) with funding from Basilea.
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